Last update :
05/12/2025
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
valistab
valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Nivolumab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Opdivo Argentina, Australia, Belgium, Brazil, Chile, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Japan, Luxembourg, Mexico, Norway, Peru, Romania, Spain, Sweden, Switzerland
References   injection   References : Nivolumab  
Type Publication
2296 Manufacturer Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
4025 Poster Vieillard V, Bardo P, Akrout W, Le Guyader G, Astier A, Paul M.
Stabilité physico-chimique de solutions de Nivolumab à 1 mois.
SFPO Congress 2017 - Nantes 2017
4505 Journal Le Guyader G, Vieillard V, Mouraud S, Do B, Marabelle A, Paul M.
Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion.
Eur J Cancer 2020 ; 135: 192-202.
4652 Manufacturer Nivolumab (Opdivo®) - Summary of Product Characteristics
Bristol Myers Squibb Pharmaceuticals 2022
4895 Journal Fukudo M, Ishikawa R, Mishima K, Ono T, Matsumoto S, Tasaki Y.
Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial for Cost Savings.
JCO Oncology Practice 2020 ; 16, 10: e1134-e1142.
  Mentions Légales